



PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week

May 14, 2019

Gelesis presents first clinical data for GS500 prototype for chronic idiopathic constipation

Vedanta presents expanded Phase 1a/1b study data of lead candidate, VE303, for recurrent Clostridium difficile infection

BOSTON, May 14, 2019—[PureTech Health](#) plc (LSE: PRTC) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliates Gelesis and Vedanta Biosciences will deliver poster presentations of clinical data at Digestive Disease Week, the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Gelesis will present clinical data from a study of CSP01 (a prototype of the investigational hydrogel candidate GS500, in development for chronic idiopathic constipation (CIC)), which demonstrated that CSP01 provided a statistically significant reduction in colonic transit time in patients with CIC relative to placebo.

Vedanta Biosciences will present expanded, longer-term data from its successfully completed Phase 1a/1b study of VE303, the company’s lead, orally-administered live biotherapeutic product candidate for recurrent *Clostridium difficile* infection.

Details of the presentations are as follows:

Gelesis

Session Date and Time: May 19, 2019 from 12:00 PM to 2:00 PM

Session Title: Constipation and Other Functional Colonic Syndromes

Presentation Title: CSP01, A Novel Superabsorbent Hydrogel, Reduces Colonic Transit Time In Chronic Idiopathic Constipation: Results From A Pilot Randomized, Double-Blind, Placebo-Controlled Trial

Poster Number: Su1638

Vedanta Biosciences

Session Date and Time: May 20, 2019 from 12:00 PM to 2:00 PM

Presentation Title: VE303, A Live Biotherapeutic Product For Prevention of Recurrent *Clostridioides Difficile* (*C. Difficile*) Infection. Preliminary Results Of A Phase 1, Open-Label Healthy Volunteers Study Of Oral VE303 After Vancomycin

Poster Number: Mo1955

About PureTech Health

PureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing BIG medicines for dysfunctions of the Brain-Immune-Gut axis. The Company has gained deep insights into the connection between these systems and the resulting role in diseases that have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.

PureTech Health is advancing a rich pipeline of innovative therapies with an unbiased, non-binary, and capital efficient R&D model across its affiliates and its internal labs. PureTech’s affiliates include seven clinical-stage platforms, including one product that has been cleared by the US Food and Drug Administration (FDA) and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programmes. The PureTech Health pipeline includes ground-breaking platforms and therapeutic candidates that were developed in collaboration with some of the world’s leading experts.

PureTech’s internal research and development is centred on tissue-selective immunomodulation for the treatment of oncology, autoimmune, and CNS-related disorders, with a near-term focus on targeting newly-discovered, foundational immunosuppressive mechanisms in oncology and novel approaches that harness the lymphatic infrastructure.

For more information, visit www.puretechhealth.com or connect with us on Twitter [@puretechh](https://twitter.com/puretechh).

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking

statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.